Equity/Index & Cross Asset Volatility Specialist, Cameron Design

Jay Cameron

With nearly two decades of experience across sell side and brokerage platforms, I specialize in quantitative research on equity derivatives and cross-asset strategies. My work focuses on translating market data into volatility-centered frameworks—integrating fundamental views, statistical models, technical analysis, Artificial Intelligence, and trading intuition to identify asymmetries and quantitative driven opportunities. I cover Japan and US with an emphasis on hedged dispersion style trades, correlation, complementing long-short ideas.

Equity/Index & Cross Asset Volatility Specialist

Cameron Design

We specialize in financial products and volatility. Our strategies balance speed, data, and risk control to capture opportunities across global markets. Our research leverages AI and data analytics to continuously refine our algorithms and adapt to evolving market dynamics.

Equity Derivatives

<ul>
<li>BillionToOne leverages its patented Quantitative Counting Technology (QCT) to achieve superior disease detection in molecular diagnostics, positioning the firm as a leader in prenatal  testing, carrier screening, oncology testing markets.</li>
<li>Demonstrating strong operational efficiency, BLLN achieved a 113% year-over-year revenue increase in 2024 and a 65% gross margin in the first half of 2025, suggesting a path to sustained profitability.</li>
<li>With a successful public debut, the recent price pullback, and an additional oncology pipeline slated for 2026, the company presents an intriguing opportunity for strategic long-term position building.</li>
</ul>


BillionToOne leverages its patented Quantitative Counting Technology (QCT) to achieve superior disease detection in molecular diagnostics, positioning the firm as a leader in prenatal  testing, carrier screening, oncology testing markets.
Demonstrating strong operational efficiency, BLLN achieved a 113% year-over-year revenue increase in 2024 and a 65% gross margin in the first half of 2025, suggesting a path to sustained profitability.
With a successful public debut, the recent price pullback, and an additional oncology pipeline slated for 2026, the company presents an intriguing opportunity for strategic long-term position building.


BillionToOne: More Than 60% Above IPO Pricing, What’s Ahead?